Tags

Type your tag names separated by a space and hit enter

Immunogenicity of aerosol measles vaccine given as the primary measles immunization to nine-month-old Mexican children.
Vaccine. 2006 Jan 30; 24(5):683-90.V

Abstract

Aerosol measles vaccination has been found to be more immunogenic than subcutaneous administration as a booster in school aged children, and immunogenic in 12-month-old children as a primary dose. The objective of the study was to evaluate immunogenicity to aerosol measles vaccine in 9-month-old children.

METHODS

Nine-months-old infants received Edmonston-Zagreb measles vaccine by aerosol (10(3.58) CCID50/0.1 mL, estimated retained dose 10(2.81) CCID50 or subcutaneous route (10(4.28) CCID50/0.5 mL); cellular and humoral immunity and adverse events were assessed.

RESULTS

Measles-specific T cell proliferative responses developed in 42% of children given aerosolized vaccine compared with 67% of those who received subcutaneous vaccine (p = 0.01); the mean stimulation index (SI) was 4.4+/-0.7 versus 6.9+/-1, respectively, (p = 0.05). Seroconversion rates were 33 and 92% after aerosol or subcutaneous immunization (p < 0.001). Among infants who developed serologic responses, measles geometric mean titers (GMT; 95% CI) by neutralizing antibody assay were 215 mIU/mL (115-400) in aerosol vaccine recipients and 411 mIU/mL (345-490) in those given subcutaneous vaccine (p = 0.06).

CONCLUSIONS

The proportion of 9-month-old infants who developed cellular and/or humoral immunity to measles was lower in the aerosol group but measles antibody and T cell responses were comparable among those who developed measles immunity. Differences in response rates are attributable to the lower aerosol dose. Improving aerosol delivery or increasing the dose may enhance immunogenicity of primary aerosol measles vaccination in this age group.

Authors+Show Affiliations

Wong-Chew RM
Departamento de Medicina Experimental, Facultad de Medicina, Universidad Nacional Autónoma de México, Dr. Balmis # 148, Colonia Doctores, 06726 Mexico City, México. rmwong@correo.unam.mx
Islas-Romero R
No affiliation info available
García-García Mde L
No affiliation info available
Beeler JA
No affiliation info available
Audet S
No affiliation info available
Santos-Preciado JI
No affiliation info available
Gans H
No affiliation info available
Lew-Yasukawa L
No affiliation info available
Maldonado YA
No affiliation info available
Arvin AM
No affiliation info available
Valdespino-Gómez JL
No affiliation info available

MeSH

AerosolsAntibodies, ViralAntibody FormationCell ProliferationDose-Response Relationship, ImmunologicFemaleHumansImmunity, CellularImmunizationInfantInjections, SubcutaneousInterferon-gammaMaleMeaslesMeasles VaccineMexicoT-LymphocytesVaccines, AttenuatedViral Plaque Assay

Pub Type(s)

Comparative Study
Journal Article
Research Support, N.I.H., Extramural

Language

eng

PubMed ID

16154241

Clinical Trial Links

Clinical Trial to Evaluate the Immunogenicity and Safety of the Vaccine Against Influenza A/H1N1

Citation

Wong-Chew, Rosa María, et al. "Immunogenicity of Aerosol Measles Vaccine Given as the Primary Measles Immunization to Nine-month-old Mexican Children." Vaccine, vol. 24, no. 5, 2006, pp. 683-90.
Wong-Chew RM, Islas-Romero R, García-García Mde L, et al. Immunogenicity of aerosol measles vaccine given as the primary measles immunization to nine-month-old Mexican children. Vaccine. 2006;24(5):683-90.
Wong-Chew, R. M., Islas-Romero, R., García-García, M. d. e. . L., Beeler, J. A., Audet, S., Santos-Preciado, J. I., Gans, H., Lew-Yasukawa, L., Maldonado, Y. A., Arvin, A. M., & Valdespino-Gómez, J. L. (2006). Immunogenicity of aerosol measles vaccine given as the primary measles immunization to nine-month-old Mexican children. Vaccine, 24(5), 683-90.
Wong-Chew RM, et al. Immunogenicity of Aerosol Measles Vaccine Given as the Primary Measles Immunization to Nine-month-old Mexican Children. Vaccine. 2006 Jan 30;24(5):683-90. PubMed PMID: 16154241.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Immunogenicity of aerosol measles vaccine given as the primary measles immunization to nine-month-old Mexican children. AU - Wong-Chew,Rosa María, AU - Islas-Romero,Rocío, AU - García-García,María de Lourdes, AU - Beeler,Judy A, AU - Audet,Susette, AU - Santos-Preciado,Jose Ignacio, AU - Gans,Hayley, AU - Lew-Yasukawa,Linda, AU - Maldonado,Yvonne A, AU - Arvin,Ann M, AU - Valdespino-Gómez,José Luis, Y1 - 2005/08/24/ PY - 2005/04/06/received PY - 2005/06/25/revised PY - 2005/08/01/accepted PY - 2005/9/13/pubmed PY - 2006/4/21/medline PY - 2005/9/13/entrez SP - 683 EP - 90 JF - Vaccine JO - Vaccine VL - 24 IS - 5 N2 - UNLABELLED: Aerosol measles vaccination has been found to be more immunogenic than subcutaneous administration as a booster in school aged children, and immunogenic in 12-month-old children as a primary dose. The objective of the study was to evaluate immunogenicity to aerosol measles vaccine in 9-month-old children. METHODS: Nine-months-old infants received Edmonston-Zagreb measles vaccine by aerosol (10(3.58) CCID50/0.1 mL, estimated retained dose 10(2.81) CCID50 or subcutaneous route (10(4.28) CCID50/0.5 mL); cellular and humoral immunity and adverse events were assessed. RESULTS: Measles-specific T cell proliferative responses developed in 42% of children given aerosolized vaccine compared with 67% of those who received subcutaneous vaccine (p = 0.01); the mean stimulation index (SI) was 4.4+/-0.7 versus 6.9+/-1, respectively, (p = 0.05). Seroconversion rates were 33 and 92% after aerosol or subcutaneous immunization (p < 0.001). Among infants who developed serologic responses, measles geometric mean titers (GMT; 95% CI) by neutralizing antibody assay were 215 mIU/mL (115-400) in aerosol vaccine recipients and 411 mIU/mL (345-490) in those given subcutaneous vaccine (p = 0.06). CONCLUSIONS: The proportion of 9-month-old infants who developed cellular and/or humoral immunity to measles was lower in the aerosol group but measles antibody and T cell responses were comparable among those who developed measles immunity. Differences in response rates are attributable to the lower aerosol dose. Improving aerosol delivery or increasing the dose may enhance immunogenicity of primary aerosol measles vaccination in this age group. SN - 0264-410X UR - https://www.unboundmedicine.com/medline/citation/16154241/Immunogenicity_of_aerosol_measles_vaccine_given_as_the_primary_measles_immunization_to_nine_month_old_Mexican_children_ DB - PRIME DP - Unbound Medicine ER -